Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
BörsenkürzelQNTM
Name des UnternehmensQuantum Biopharma Ltd
IPO-datumMay 29, 2018
CEODr. Lakshmi P. Kotra, Ph.D.
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeMay 29
Addresse55 University Ave. , Suite 1003
StadtTORONTO
BörseCanadian Securities Exchange - CSE Listed
LandCanada
PostleitzahlM5J 2H7
Telefon14168548884
Websitehttps://www.quantumbiopharma.com/
BörsenkürzelQNTM
IPO-datumMay 29, 2018
CEODr. Lakshmi P. Kotra, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten